|Mr. Richard J. Hawkins||CEO & Chairman||1.27M||N/A||1949|
|Dr. John C. McKew Ph.D.||Chief Scientific Officer & Pres||747.99k||N/A||1964|
|Mr. Bradley J. Powers J.D.||Chief Compliance Officer & Gen. Counsel||677.08k||N/A||1979|
|Mr. Carl W. Langren||Consultant||717.99k||N/A||1955|
|Ms. Lori D. Lawley CPA||CFO & Principal Accounting Officer||N/A||N/A||1984|
|Lisa Miller||Sr. Director of Investor Relations||N/A||N/A||N/A|
|Mr. Aaron Schuchart B.B.A., CPA, M.B.A.||Chief Bus. Officer||N/A||N/A||1965|
|Dr. David B. Karpf B.A., M.D.||Chief Medical Officer||N/A||N/A||1955|
|Mr. Eddie L. Varnado M.B.A.||VP of Fin. & Corp. Controller||N/A||N/A||N/A|
Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for rare diseases. Its lead therapeutic candidate LUM-201 is an oral growth hormone stimulating small molecule, which is in Phase 2b clinical trial for the treatment of pediatric growth hormone deficiency. The company was founded in 2011 and is headquartered in Austin, Texas.
Lumos Pharma, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.